Julian Hercun
Overview
Explore the profile of Julian Hercun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gopalakrishna H, Hercun J, Shah N, Roschewski M, Rotman Y
Liver Int
. 2025 Feb;
45(3):e70022.
PMID: 39927416
Background And Aims: Hepatotoxicity is a known risk of oral and intravenous methotrexate (MTX), but whether intrathecal (IT) administration causes hepatotoxicity remains unknown. We aimed to explore whether IT-MTX causes...
2.
Razavi H, Waked I, Qureshi H, Kondili L, Duberg A, Aleman S, et al.
J Hepatol
. 2025 Feb;
PMID: 39914746
Background And Aims: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by...
3.
Coman D, Bilodeau M, Vincent C, Brochiero E, Lavoie A, Hercun J
Dig Dis Sci
. 2024 Dec;
70(2):526-532.
PMID: 39671064
Background: The reported prevalence of cystic fibrosis (CF)-related liver disease (CFLD) reaches up to 40% in some cohorts. CFLD is the 3rd leading cause of mortality among patients with CF....
4.
Hercun J, Asif B, Vittal A, Ahmed A, Gopalakrishna Pillai H, Bergerson J, et al.
Aliment Pharmacol Ther
. 2024 Aug;
60(7):888-896.
PMID: 39090843
Background And Aims: Liver involvement is an increasingly recognised complication of common variable immunodeficiency (CVID). Nodular regenerative hyperplasia (NRH), a subgroup of porto-sinusoidal vascular disorder, and manifestations of portal hypertension...
5.
Mironova M, Gopalakrishna H, Viana Rodriguez G, Majeed N, Hitawala A, Fuss I, et al.
Aliment Pharmacol Ther
. 2024 Apr;
59(12):1527-1538.
PMID: 38629442
Background: Non-cirrhotic portal hypertension (NCPH) is a spectrum of liver diseases, including porto-sinusoidal vascular disorder, with portal hypertension (PH) in the absence of cirrhosis. The natural history and diagnostic approach...
6.
Plagiannakos C, Hirschfield G, Lytvyak E, Roberts S, Ismail M, Gulamhusein A, et al.
J Hepatol
. 2024 Mar;
81(2):227-237.
PMID: 38527524
Background & Aims: Treatment outcomes for people living with autoimmune hepatitis (AIH) are limited by a lack of specific therapies, as well as limited well-validated prognostic tools and clinical trial...
7.
Coman D, Vincent C, Huard G, Marleau D, Lavoie A, Hercun J
J Cyst Fibros
. 2023 Nov;
23(3):561-562.
PMID: 38000917
No abstract available.
8.
Vittal A, Niewisch M, Bhala S, Kudaravalli P, Rahman F, Hercun J, et al.
Hepatology
. 2023 May;
78(6):1777-1787.
PMID: 37184208
Background And Aims: Dyskeratosis congenita (DC) and related telomere biology disorders (TBD) are characterized by very short telomeres and multisystem organ involvement including liver disease. Our study aimed to characterize...
9.
Hercun J, Willems P, Bilodeau M, Vincent C, Alvarez F
JPGN Rep
. 2023 May;
3(3):e220.
PMID: 37168634
Methods: We reviewed records of patients followed for PSC or AIC between 1998 and 2019 at a pediatric referral center. Features at diagnosis, biochemical and liver-related outcomes (cholangitis, liver transplant,...
10.
Hercun J, Heller T, Glenn J, Kleiner D, Koh C
Front Med (Lausanne)
. 2023 Apr;
10:1082069.
PMID: 37089591
Background: Chronic hepatitis delta virus (HDV) infection leads to a more severe hepatitis than hepatitis B virus (HBV) infection alone. Specific histological staining patterns have been described in HBV mono-infection,...